| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
- |
| Employees |
5 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-12 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Rain Therapeutics Inc. is a clinical-stage biotechnology company that was founded in 2017 and is headquartered in Newark, California. The company is focused on developing targeted therapies for cancer patients. Rain Therapeutics aims to provide effective therapies to patients who have limited treatment options.
The company's lead drug candidate is called RAIN-32, which targets a specific genetic mutation that is present in a variety of tumors, including non-Hodgkin's lymphoma, solid tumors, and certain types of leukemia. RAIN-32 is currently in clinical testing, and the preliminary results have been promising. Rain Therapeutics also has several other drug candidates in preclinical development.
Rain Therapeutics is led by a team of experienced executives with a track record of success in the biotechnology industry. The company's CEO is Avanish Vellanki, who has over 20 years of experience in the biotech industry.
In addition to its focus on developing targeted therapies, Rain Therapeutics is committed to addressing the unmet needs of cancer patients. The company is actively engaged in working with advocacy groups to raise awareness about the disease and the need for new treatments.
Rain Therapeutics has raised over $120 million in funding to date from investors, including RTW Investments, BVF Partners, and Perceptive Advisors. The company is well-positioned to advance its drug candidates through clinical development and bring new therapies to patients who need them.
Company Address: 4851 Tamiami Trail N Naples 34103 FL
Company Phone Number: 222-6714 Stock Exchange / Ticker: NASDAQ RAIN
|
